

# Eunice S Wang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6532111/publications.pdf>

Version: 2024-02-01

228  
papers

8,273  
citations

61984

43  
h-index

58581

82  
g-index

229  
all docs

229  
docs citations

229  
times ranked

9844  
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical and molecular relevance of genetic variants in the non-coding transcriptome of patients with cytogenetically normal acute myeloid leukemia. <i>Haematologica</i> , 2022, 107, 1034-1044.	3.5	4
2	Molecular, clinical, and prognostic implications of <i>PTPN11</i> mutations in acute myeloid leukemia. <i>Blood Advances</i> , 2022, 6, 1371-1380.	5.2	16
3	Menin Inhibitors in Acute Myeloid Leukemia—What Does the Future Hold?. <i>Cancer Journal (Sudbury, MA)</i> 2022, 28, 1078-1088.	2.0	28
4	Mutant <i>PPM1D</i> - and <i>TP53</i> -Driven Hematopoiesis Populates the Hematopoietic Compartment in Response to Peptide Receptor Radionuclide Therapy. <i>JCO Precision Oncology</i> , 2022, 6, e2100309.	3.0	15
5	<i>BCOR</i> and <i>BCORL1</i> Mutations Drive Epigenetic Reprogramming and Oncogenic Signaling by Unlinking PRC1.1 from Target Genes. <i>Blood Cancer Discovery</i> , 2022, 3, 116-135.	5.0	18
6	Long-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm. <i>Journal of Clinical Oncology</i> , 2022, 40, 3032-3036.	1.6	19
7	PARP goes the weasel! Emerging role of PARP inhibitors in acute leukemias. <i>Blood Reviews</i> , 2021, 45, 100696.	5.7	17
8	Germline variants drive myelodysplastic syndrome in young adults. <i>Leukemia</i> , 2021, 35, 2439-2444.	7.2	43
9	A Phase II Trial of Imatinib Mesylate as Maintenance Therapy for Patients With Newly Diagnosed C-kit-positive Acute Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 113-118.	0.4	4
10	Cladribine, cytarabine, and GCSF with and without mitoxantrone (CLAG±M) is highly effective for poor risk acute myeloid leukemia with adverse karyotype and prior hypomethylating therapy. <i>Leukemia and Lymphoma</i> , 2021, 62, 1778-1781.	1.3	2
11	Inhibiting autophagy targets human leukemic stem cells and hypoxic AML blasts by disrupting mitochondrial homeostasis. <i>Blood Advances</i> , 2021, 5, 2087-2100.	5.2	23
12	A precision medicine classification for treatment of acute myeloid leukemia in older patients. <i>Journal of Hematology and Oncology</i> , 2021, 14, 96.	17.0	5
13	Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms. <i>Leukemia</i> , 2021, 35, 3542-3550.	7.2	97
14	Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance). <i>Blood Advances</i> , 2021, 5, 2775-2787.	5.2	15
15	A phase 2 trial of single low doses of rasburicase for treatment of hyperuricemia in adult patients with acute leukemia. <i>Leukemia Research</i> , 2021, 107, 106588.	0.8	3
16	Acute Myeloid Leukemia: Historical Perspective and Progress in Research and Therapy Over 5 Decades. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 580-597.	0.4	28
17	Risk, Characteristics and Biomarkers of Cytokine Release Syndrome in Patients with Relapsed/Refractory AML or MDS Treated with CD3xCD123 Bispecific Antibody APVO436. <i>Cancers</i> , 2021, 13, 5287.	3.7	4
18	Harnessing the benefits of available targeted therapies in acute myeloid leukaemia. <i>Lancet Haematology</i> , 2021, 8, e922-e933.	4.6	27

#	ARTICLE	IF	CITATIONS
19	<i>DNMT3A</i> and <i>TET2</i> mutant Clonal Hematopoiesis May Drive a Proinflammatory State and Predict Enhanced Response to Immune Checkpoint Inhibitors. <i>Blood</i> , 2021, 138, 4295-4295.	1.4	2
20	Phase 1b Trial of Talazoparib and Gemtuzumab Ozogamicin in Adult Patients with CD33+ Relapsed or Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2021, 138, 4435-4435.	1.4	1
21	Phase I Dose-Finding Study of Eltrombopag Following High Dose Cytarabine and Mitoxantrone Chemotherapy in Patients with Relapsed/Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2021, 138, 4426-4426.	1.4	0
22	PARP Inhibition with Talazoparib Enhances DNA Damage and Anti-Leukemic Activity of Venetoclax in Preclinical Human Acute Myeloid Leukemia (AML) Models. <i>Blood</i> , 2021, 138, 1176-1176.	1.4	0
23	Association between the Leukemia Mortality-to-Incidence Ratio and State Geographic Healthcare Disparities in the United States. <i>Blood</i> , 2021, 138, 3066-3066.	1.4	0
24	Age, Sex and Self-Reported Race Differences in Immune Profiles of Hematologic Malignancy Patients. <i>Blood</i> , 2021, 138, 4066-4066.	1.4	0
25	<i>ASXL1</i> Mutation Is a Novel Risk Factor for Bleeding in Patients with Philadelphia-Negative Myeloproliferative Neoplasms (MPN). <i>Blood</i> , 2021, 138, 3637-3637.	1.4	1
26	Safety and Efficacy of CPX-351 in Younger Patients &lt; 60 Years Old with Secondary Acute Myeloid Leukemia: An Updated Analysis. <i>Blood</i> , 2021, 138, 1264-1264.	1.4	5
27	A Phase I Study of Asciminib (ABLO01) in Combination with Dasatinib and Prednisone for BCR-ABL1-Positive ALL in Adults. <i>Blood</i> , 2021, 138, 2305-2305.	1.4	12
28	Targeting acute myeloid leukemia through multimodal immunotherapeutic approaches. <i>Leukemia and Lymphoma</i> , 2021, , 1-10.	1.3	1
29	Emerging trends of therapy related myeloid neoplasms following modern cancer therapeutics in the United States. <i>Scientific Reports</i> , 2021, 11, 23284.	3.3	3
30	Post-hoc Analysis of Pharmacodynamics and Single-Agent Activity of CD3xCD123 Bispecific Antibody APVO436 in Relapsed/Refractory AML and MDS Resistant to HMA or Venetoclax Plus HMA. <i>Frontiers in Oncology</i> , 2021, 11, 806243.	2.8	1
31	Prevention, recognition, and management of adverse events associated with gemtuzumab ozogamicin use in acute myeloid leukemia. <i>Journal of Hematology and Oncology</i> , 2020, 13, 137.	17.0	23
32	Favorable outcomes of acute leukemias of ambiguous lineage treated with hyperCVAD: a multi-center retrospective study. <i>Annals of Hematology</i> , 2020, 99, 2119-2124.	1.8	7
33	Management of toxicities associated with targeted therapies for acute myeloid leukemia: when to push through and when to stop. <i>Hematology American Society of Hematology Education Program</i> , 2020, 2020, 57-66.	2.5	13
34	Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts. <i>Lancet Haematology</i> , 2020, 7, e601-e612.	4.6	56
35	Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results. <i>Leukemia</i> , 2020, 34, 2903-2913.	7.2	38
36	Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phase. <i>Blood Advances</i> , 2020, 4, 5246-5256.	5.2	45

#	ARTICLE	IF	CITATIONS
37	Safety of gemtuzumab ozogamicin as monotherapy or combination therapy in an expanded-access protocol for patients with relapsed or refractory acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2020, 61, 1965-1973.	1.3	10
38	A phase 1/2 study of the oral FLT3 inhibitor pexidartinib in relapsed/refractory FLT3-ITD mutant acute myeloid leukemia. <i>Blood Advances</i> , 2020, 4, 1711-1721.	5.2	30
39	Comparison of induction strategies and responses for acute myeloid leukemia patients after resistance to hypomethylating agents for antecedent myeloid malignancy. <i>Leukemia Research</i> , 2020, 93, 106367.	0.8	15
40	Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801. <i>Blood Advances</i> , 2020, 4, 696-705.	5.2	44
41	Clinical and functional significance of circular RNAs in cytogenetically normal AML. <i>Blood Advances</i> , 2020, 4, 239-251.	5.2	29
42	Novel therapies for AML: a round-up for clinicians. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 1389-1400.	3.1	21
43	A Phase Ib Study of Onvansertib, a Novel Oral PLK1 Inhibitor, in Combination Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2020, 26, 6132-6140.	7.0	45
44	Novel and Emerging Treatment Strategies for Acute Myeloid Leukemia. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 999-1003.	4.9	0
45	Clonal Hematopoiesis in Patients with Neuroendocrine Tumors Receiving Peptide Receptor Radionuclide Therapy (PRRT). <i>Blood</i> , 2020, 136, 35-36.	1.4	0
46	Biomarker Driven Umbrella Trial of Crenolanib in Combination with Ivosidenib, Enasidenib, Venetoclax, Vyxeos and/or Salvage Chemotherapy in FLT3 Mutant AML. <i>Blood</i> , 2020, 136, 16-17.	1.4	1
47	Phase 1/1b Trial of Talazoparib and Gemtuzumab Ozogamicin in Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 20-21.	1.4	0
48	Clonal Hematopoiesis in Patients Receiving Immune Checkpoint Inhibitor Therapy. <i>Blood</i> , 2020, 136, 15-16.	1.4	0
49	Genetic Characterization and Prognostic Relevance of Acquired Uniparental Disomies in Cytogenetically Normal Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2019, 25, 6524-6531.	7.0	12
50	Advancing treatment of acute myeloid leukemia: the future of FLT3 inhibitors. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 273-286.	2.4	20
51	Gilteritinib for the treatment of patients with FLT3 mutated relapsed or refractory acute myeloid leukemia. <i>Expert Review of Precision Medicine and Drug Development</i> , 2019, 4, 105-112.	0.7	2
52	Prognostic and Biologic Relevance of Clinically Applicable Long Noncoding RNA Profiling in Older Patients with Cytogenetically Normal Acute Myeloid Leukemia. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1451-1459.	4.1	7
53	Incorporating FLT3 inhibitors in the frontline treatment of FLT3 mutant acute myeloid leukemia. <i>Best Practice and Research in Clinical Haematology</i> , 2019, 32, 154-162.	1.7	12
54	Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia. <i>Cancer Discovery</i> , 2019, 9, 1050-1063.	9.4	288

#	ARTICLE	IF	CITATIONS
55	Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm. <i>New England Journal of Medicine</i> , 2019, 380, 1628-1637.	27.0	274
56	Mitochondrial hypoxic stress induces widespread RNA editing by APOBEC3G in natural killer cells. <i>Genome Biology</i> , 2019, 20, 37.	8.8	50
57	Complex karyotype in de novo acute myeloid leukemia: typical and atypical subtypes differ molecularly and clinically. <i>Leukemia</i> , 2019, 33, 1620-1634.	7.2	55
58	Phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in relapsed/refractory acute myeloid leukemia. <i>Blood Advances</i> , 2019, 3, 1939-1949.	5.2	63
59	Beyond midostaurin: Which are the most promising FLT3 inhibitors in AML?. <i>Best Practice and Research in Clinical Haematology</i> , 2019, 32, 101103.	1.7	9
60	What potential is there for LSD1 inhibitors to reach approval for AML?. <i>Expert Opinion on Emerging Drugs</i> , 2019, 24, 205-212.	2.4	14
61	Genome-wide association study identifies an acute myeloid leukemia susceptibility locus near BICRA. <i>Leukemia</i> , 2019, 33, 771-775.	7.2	15
62	Genetic Alterations at Diagnosis Predict Outcome of AML Patients Age 60 or Older Undergoing Allogeneic Transplantation in First Remission. <i>Blood</i> , 2019, 134, 48-48.	1.4	4
63	Results from ongoing phase 1/2 clinical trial of tagraxofusp (SL-401) in patients with intermediate or high risk relapsed/refractory myelofibrosis.. <i>Journal of Clinical Oncology</i> , 2019, 37, 7058-7058.	1.6	6
64	Results from ongoing phase 1/2 clinical trial of tagraxofusp (SL-401) in patients with relapsed/refractory chronic myelomonocytic leukemia (CMML).. <i>Journal of Clinical Oncology</i> , 2019, 37, 7059-7059.	1.6	9
65	Crenolanib versus midostaurin combined with induction and consolidation chemotherapy in newly diagnosed FLT3 mutated AML.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS7068-TPS7068.	1.6	8
66	Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2019. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 414-423.	4.9	44
67	Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 721-749.	4.9	314
68	Cladribine, Cytarabine, Granulocyte Colony Stimulating Factor ± Mitoxantrone (CLAG ± M) Is Highly Effective Therapy for Secondary and Relapsed/Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 1361-1361.	1.4	0
69	Benefits of a Pharmacist Led Oral Chemotherapy Monitoring Program for Patients with Chronic Myeloid Malignancies: A Patient Reported Outcome (PRO) Study. <i>Blood</i> , 2019, 134, 3501-3501.	1.4	1
70	Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of Alliance studies. <i>Leukemia</i> , 2018, 32, 1338-1348.	7.2	80
71	Role of Chromatin Damage and Chromatin Trapping of FACT in Mediating the Anticancer Cytotoxicity of DNA-Binding Small-Molecule Drugs. <i>Cancer Research</i> , 2018, 78, 1431-1443.	0.9	60
72	Combining blinatumomab with targeted therapy for BCR-ABL mutant relapsed/refractory acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 2011-2013.	1.3	7

#	ARTICLE	IF	CITATIONS
73	High dose daunorubicin: New standard of care for FLT3 ITD mutant AML. <i>Leukemia Research</i> , 2018, 69, 87-88.	0.8	1
74	IMGN779, a Novel CD33-Targeting Antibody-Drug Conjugate with DNA-Alkylating Activity, Exhibits Potent Antitumor Activity in Models of AML. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 1271-1279.	4.1	60
75	Advances in immunotherapy for acute myeloid leukemia. <i>Future Oncology</i> , 2018, 14, 963-978.	2.4	32
76	NY-ESO-1 Vaccination in Combination with Decitabine Induces Antigen-Specific T-lymphocyte Responses in Patients with Myelodysplastic Syndrome. <i>Clinical Cancer Research</i> , 2018, 24, 1019-1029.	7.0	87
77	Intensive chemotherapy vs. hypomethylating agents in older adults with newly diagnosed high-risk acute myeloid leukemia: A single center experience. <i>Leukemia Research</i> , 2018, 75, 29-35.	0.8	20
78	Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance). <i>Blood Advances</i> , 2018, 2, 3608-3617.	5.2	39
79	Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 549-559.	3.1	75
80	Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2018, 19, 889-903.	10.7	205
81	Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study results. <i>American Journal of Hematology</i> , 2018, 93, 1301-1310.	4.1	98
82	All-trans-retinoic-acid and arsenic trioxide induced remission in promyelocytic blast crisis. <i>Leukemia Research Reports</i> , 2018, 10, 16-19.	0.4	5
83	NF1 mutations are recurrent in adult acute myeloid leukemia and confer poor outcome. <i>Leukemia</i> , 2018, 32, 2536-2545.	7.2	33
84	Safety of Gemtuzumab Ozogamicin As Monotherapy or Combination Therapy in an Expanded-Access Protocol for Patients with Relapsed or Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 3979-3979.	1.4	2
85	Multicenter, Open-Label, 3-Arm Study of Gilteritinib, Gilteritinib Plus Azacitidine, or Azacitidine Alone in Newly Diagnosed FLT3 Mutated (FLT3mut+) Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Induction Chemotherapy: Findings from the Safety Cohort. <i>Blood</i> , 2018, 132, 2736-2736.	1.4	44
86	Remissions in Relapse/Refractory Acute Myeloid Leukemia Patients Following Treatment with NKG2D CAR-T Therapy without a Prior Preconditioning Chemotherapy. <i>Blood</i> , 2018, 132, 902-902.	1.4	19
87	Efficacy of Combined Ruxolitinib and Decitabine in Patients with Accelerated and Blast-Phase Myeloproliferative Neoplasms: Results of a Phase II Study (MPN-RC 109 trial). <i>Blood</i> , 2018, 132, 3027-3027.	1.4	5
88	Maturing Clinical Profile of IMGN779, a Next-Generation CD33-Targeting Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 26-26.	1.4	25
89	A Phase I, First-in-Human Study Evaluating the Safety and Preliminary Antileukemia Activity of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Other CD123-Positive Hematologic Malignancies. <i>Blood</i> , 2018, 132, 27-27.	1.4	29
90	Safety and Efficacy of Liposomal Cytarabine/Daunorubicin (CPX-351) in Younger Patients < 60 Years Old with Secondary Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 2677-2677.	1.4	1

#	ARTICLE	IF	CITATIONS
91	FT-2102, an IDH1m Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Aynndrome (MDS): Results from a Phase 1 Study. <i>Blood</i> , 2018, 132, 1452-1452.	1.4	16
92	Phase 1 Studies Assessing the Safety and Clinical Activity of Multiple Doses of a NKG2D-Based CAR-T Therapy, Cyad-01, in Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 1398-1398.	1.4	2
93	Zella 201: A Biomarker-Guided Phase II Study of Alvocidib Followed By Cytarabine and Mitoxantrone in MCL-1 Dependent Relapsed/Refractory Acute Myeloid Leukemia (AML). <i>Blood</i> , 2018, 132, 30-30.	1.4	7
94	Chloroquine Derivative Lys05 Overcomes Hypoxia-Induced Chemoresistance in Acute Myeloid Leukemia through Metabolic Disruption. <i>Blood</i> , 2018, 132, 3948-3948.	1.4	1
95	Synergistic Anti-Leukemic Activity of PARP Inhibition Combined with IMG632, an Anti-CD123 Antibody-Drug Conjugate in Acute Myeloid Leukemia Models. <i>Blood</i> , 2018, 132, 2647-2647.	1.4	3
96	Results of Pivotal Phase 2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). <i>Blood</i> , 2018, 132, 765-765.	1.4	9
97	Clinical Outcomes for Patients with Myeloid Malignancies Harboring IDH1/2mutations after Intensive Chemotherapy. <i>Blood</i> , 2018, 132, 1389-1389.	1.4	1
98	Comparison of Induction Strategies and Responses for Acute Myeloid Leukemia Patients after Resistance to Hypomethylating Agents for Antecedent Myeloid Malignancy. <i>Blood</i> , 2018, 132, 665-665.	1.4	5
99	Increased Monocytic Myeloid-Derived Suppressor Cells in the Marrow of Relapsed/Refractory Acute Myeloid Leukemia Patients Following Induction Chemotherapy. <i>Blood</i> , 2018, 132, 5270-5270.	1.4	2
100	Prognostic and Biologic Significance of Transfer RNA-Derived Small RNAs (tsRNAs) Expression in Younger Adult Patients (Pts) with Cytogenetically Normal Acute Myeloid Leukemia (CN-AML). <i>Blood</i> , 2018, 132, 89-89.	1.4	9
101	Favorable Outcomes of Acute Leukemia of Ambiguous Lineage Treated with Hypercvad: A Multi-Center Retrospective Study. <i>Blood</i> , 2018, 132, 2658-2658.	1.4	0
102	Prognostic and Biologic Significance of Long Non-Coding RNA (lncRNA) Profiling in Cytogenetically Abnormal Acute Myeloid Leukemia (CA-AML). <i>Blood</i> , 2018, 132, 2767-2767.	1.4	0
103	Genome-Wide Association Study (GWAS) Identifies a Significant Acute Myeloid Leukemia (AML) Susceptibility Locus Near BICRA. <i>Blood</i> , 2018, 132, 85-85.	1.4	0
104	Clinical and Molecular Variables Associated with Atherosclerotic Vascular Disease in Myelodysplastic Syndromes. <i>Blood</i> , 2018, 132, 4366-4366.	1.4	0
105	A Precision Medicine Heirarchical Classification Developed Using Variant Allele Frequency (VAF) for Treatment of Older Patients (Pts) with Acute Myeloid Leukemia (AML): Alliance Clinical Trials in Oncology (Alliance) Historical Patient Control. <i>Blood</i> , 2018, 132, 1489-1489.	1.4	1
106	Dexrazoxane for cardioprotection in older adults with acute myeloid leukemia. <i>Leukemia Research Reports</i> , 2017, 7, 36-39.	0.4	12
107	Prognostic and biologic significance of long non-coding RNA profiling in younger adults with cytogenetically normal acute myeloid leukemia. <i>Haematologica</i> , 2017, 102, 1391-1400.	3.5	28
108	Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1&acirc2 study. <i>Lancet Oncology</i> , The, 2017, 18, 1061-1075.	10.7	402

#	ARTICLE	IF	CITATIONS
109	Prognostic and biological significance of the proangiogenic factor EGFL7 in acute myeloid leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E4641-E4647.	7.1	36
110	NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 1193-1207.	4.9	119
111	NCCN Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2017. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 1091-1102.	4.9	67
112	Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 926-957.	4.9	451
113	Deep molecular response to gilteritinib to improve survival in FLT3 mutation-positive relapsed/refractory acute myeloid leukemia.. Journal of Clinical Oncology, 2017, 35, 7003-7003.	1.6	7
114	Effect of cytarabine/anthracycline/crenolanib induction on minimal residual disease (MRD) in newly diagnosed FLT3 mutant AML.. Journal of Clinical Oncology, 2017, 35, 7016-7016.	1.6	4
115	Dose escalation results of a phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in patients (Pts) with relapsed/refractory (r/r) acute myeloid leukemia (AML).. Journal of Clinical Oncology, 2017, 35, 7027-7027.	1.6	5
116	CASCADE: A phase 3, randomized, double-blind study of vadastuximab talirine (33A) versus placebo in combination with azacitidine or decitabine in the treatment of older patients with newly diagnosed acute myeloid leukemia (AML).. Journal of Clinical Oncology, 2017, 35, TPS7066-TPS7066.	1.6	7
117	Spontaneous Remission in an Older Patient with Relapsed FLT3 ITD Mutant AML. Case Reports in Hematology, 2016, 2016, 1-7.	0.4	10
118	Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 1572-1611.	4.9	61
119	Discontinuation of Systematic Surveillance and Contact Precautions for Vancomycin-Resistant <i>Enterococcus</i> (VRE) and Its Impact on the Incidence of VRE <i>faecium</i> Bacteremia in Patients with Hematologic Malignancies. Infection Control and Hospital Epidemiology, 2016, 37, 398-403.	1.8	40
120	Inhibitors of LSD1 as a potential therapy for acute myeloid leukemia. Expert Opinion on Investigational Drugs, 2016, 25, 771-780.	4.1	35
121	Evolution of acute myelogenous leukemia stem cell properties after treatment and progression. Blood, 2016, 128, 1671-1678.	1.4	179
122	Adjustment to Acute Leukemia: The Impact of Social Support and Marital Satisfaction on Distress and Quality of Life Among Newly Diagnosed Patients and Their Caregivers. Journal of Clinical Psychology in Medical Settings, 2016, 23, 298-309.	1.4	22
123	Rituximab refractory thrombotic thrombocytopenic purpura responsive to intravenous but not subcutaneous bortezomib. Transfusion, 2016, 56, 970-974.	1.6	24
124	Clinical updates in adult acute lymphoblastic leukemia. Critical Reviews in Oncology/Hematology, 2016, 99, 189-199.	4.4	30
125	Swallowing a bitter pill oral arsenic trioxide for acute promyelocytic leukemia. Blood Reviews, 2016, 30, 201-211.	5.7	22
126	A phase I study of intermediate dose cytarabine in combination with lenalidomide in relapsed/refractory acute myeloid leukemia. Leukemia Research, 2016, 43, 44-48.	0.8	10



#	ARTICLE	IF	CITATIONS
127	Polo-like kinase inhibitors in hematologic malignancies. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 98, 200-210.	4.4	29
128	Final Results of the Chrysalis Trial: A First-in-Human Phase 1/2 Dose-Escalation, Dose-Expansion Study of Gilteritinib (ASP2215) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML). <i>Blood</i> , 2016, 128, 1069-1069.	1.4	35
129	Crenolanib, a Type I FLT3 TKI, Can be Safely Combined with Cytarabine and Anthracycline Induction Chemotherapy and Results in High Response Rates in Patients with Newly Diagnosed FLT3 Mutant Acute Myeloid Leukemia (AML). <i>Blood</i> , 2016, 128, 1071-1071.	1.4	47
130	Combining IMGN779, a Novel Anti-CD33 Antibody-Drug Conjugate (ADC), with the PARP Inhibitor, Olaparib, Results in Enhanced Anti-Tumor Activity in Preclinical Acute Myeloid Leukemia (AML) Models. <i>Blood</i> , 2016, 128, 1645-1645.	1.4	11
131	Results from Ongoing Phase 2 Trial of SL-401 As Consolidation Therapy in Patients with Acute Myeloid Leukemia (AML) in Remission with High Relapse Risk Including Minimal Residual Disease (MRD). <i>Blood</i> , 2016, 128, 215-215.	1.4	25
132	Intensive Versus Non-Intensive Induction Therapy for Patients (Pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) Using Two Different Novel Prognostic Models. <i>Blood</i> , 2016, 128, 216-216.	1.4	18
133	Results from Phase 2 Trial Ongoing Expansion Stage of SL-401 in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). <i>Blood</i> , 2016, 128, 342-342.	1.4	12
134	Targeting Autophagy As a Therapeutic Strategy in Acute Myeloid Leukemia. <i>Blood</i> , 2016, 128, 3950-3950.	1.4	4
135	Targeting Innate and Adaptive Immune Responses for the Treatment of Acute Myeloid Leukemia. <i>Blood</i> , 2016, 128, 2833-2833.	1.4	1
136	The Mutational Patterns Associated with Cytogenetic Subsets of De Novo Acute Myeloid Leukemia (AML): A Study of 1603 Adult Patients (Pts). <i>Blood</i> , 2016, 128, 287-287.	1.4	0
137	Vaccination with NY-ESO-1 in Combination with Decitabine for Patients with MDS. <i>Blood</i> , 2016, 128, 4326-4326.	1.4	1
138	Acute Lymphoblastic Leukemia, Version 2.2015. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 1240-1279.	4.9	116
139	Case study interpretation-Fort Lauderdale: Case 3. , 2015, 88, 404-407.		1
140	Comparison of epigenetic versus standard induction chemotherapy for newly diagnosed acute myeloid leukemia patients ≥60 years old. <i>American Journal of Hematology</i> , 2015, 90, 639-646.	4.1	31
141	Blinatumomab: enlisting serial killer T-cells in the war against hematologic malignancies. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 895-908.	3.1	25
142	Presence of isocitrate dehydrogenase mutations may predict clinical response to hypomethylating agents in patients with acute myeloid leukemia. <i>American Journal of Hematology</i> , 2015, 90, E77-9.	4.1	69
143	Acceptability, Feasibility, and Efficacy of a Supportive Group Intervention for Caregivers of Newly Diagnosed Leukemia Patients. <i>Journal of Psychosocial Oncology</i> , 2015, 33, 163-177.	1.2	13
144	Pharmacogenetics predictive of response and toxicity in acute lymphoblastic leukemia therapy. <i>Blood Reviews</i> , 2015, 29, 243-249.	5.7	42

#	ARTICLE	IF	CITATIONS
145	How we will treat chronic myeloid leukemia in 2016. <i>Blood Reviews</i> , 2015, 29, 137-142.	5.7	15
146	An Oncologist's Perspective on Metformin Use and Acute Lymphoblastic Leukemia Outcomes. <i>Journal of Pharmacy Practice</i> , 2015, 28, 46-47.	1.0	3
147	Pharmacological targeting of $\beta$ -catenin in normal karyotype acute myeloid leukemia blasts. <i>Haematologica</i> , 2015, 100, e49-e52.	3.5	16
148	Decitabine and Sorafenib Therapy in FLT-3 ITD-Mutant Acute Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, S73-S79.	0.4	44
149	Bosutinib for the treatment of Philadelphia chromosome-positive leukemias. <i>Expert Opinion on Orphan Drugs</i> , 2015, 3, 599-608.	0.8	3
150	Revisiting the role of cladribine in acute myeloid leukemia: An improvement on past accomplishments or more old news?. <i>American Journal of Hematology</i> , 2015, 90, 62-72.	4.1	37
151	CLAG-M (cladribine, cytarabine, granulocyte colony stimulating factor $\pm$ mitoxantrone) Results in High Response Rates in Older Patients with Secondary and Relapsed/Refractory Acute Myeloid Leukemia - a Single Institute Experience. <i>Blood</i> , 2015, 126, 1341-1341.	1.4	1
152	Phase 1 Study of CB-839, a First-in-Class, Orally Administered Small Molecule Inhibitor of Glutaminase in Patients with Relapsed/Refractory Leukemia. <i>Blood</i> , 2015, 126, 2566-2566.	1.4	31
153	NY-ESO-1 Vaccination in Combination with Decitabine for Patients with MDS Induces CD4+ and CD8+ T-Cell Responses. <i>Blood</i> , 2015, 126, 2873-2873.	1.4	3
154	Antileukemic Activity and Tolerability of ASP2215 80mg and Greater in FLT3 Mutation-Positive Subjects with Relapsed or Refractory Acute Myeloid Leukemia: Results from a Phase 1/2, Open-Label, Dose-Escalation/Dose-Response Study. <i>Blood</i> , 2015, 126, 321-321.	1.4	19
155	Lead-in Stage Results of a Pivotal Trial of SL-401, an Interleukin-3 Receptor (IL-3R) Targeting Biologic, in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) or Acute Myeloid Leukemia (AML). <i>Blood</i> , 2015, 126, 3795-3795.	1.4	15
156	A Role for IL1RAP in Acute Myelogenous Leukemia Stem Cells Following Treatment and Progression. <i>Blood</i> , 2015, 126, 4266-4266.	1.4	1
157	A Phase 1b Study of Birinapant in Combination with 5-Azacitadine in Patients with Myelodysplastic Syndrome Who Are Naïve, Refractory or Have Relapsed to 5-Azacitadine. <i>Blood</i> , 2015, 126, 93-93.	1.4	3
158	Results of a first-in-human, phase I/II trial of ASP2215, a selective, potent inhibitor of FLT3/Axl in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML).. <i>Journal of Clinical Oncology</i> , 2015, 33, 7003-7003.	1.6	28
159	Plasma Vincristine Levels Are 100-Fold Higher with Marqibo® (Vincristine Sulfate LIPOSOME Injection) in Place of Standard Vincristine in Combination Chemotherapy of Patients $\geq$ 60 Years Old with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2015, 126, 2491-2491.	1.4	14
160	Functional Genomics and Computational Approaches Identify Novel Small Molecules Targeting Quiescent Leukemia Stem Cells. <i>Blood</i> , 2015, 126, 1391-1391.	1.4	0
161	Optimizing Effects of mTOR Inhibition in Acute Myelogenous Leukemia. <i>Blood</i> , 2015, 126, 4930-4930.	1.4	0
162	Long-Term Follow-up Results: A Phase 2 Trial of Imatinib Mesylate As Maintenance Therapy for Patients with Newly Diagnosed c-Kit Positive Acute Myeloid Leukemia (AML). <i>Blood</i> , 2015, 126, 2536-2536.	1.4	0

#	ARTICLE	IF	CITATIONS
163	Treating acute myeloid leukemia in older adults. Hematology American Society of Hematology Education Program, 2014, 2014, 14-20.	2.5	71
164	Deletion and deletion/insertion mutations in the juxtamembrane domain of the FLT3 gene in adult acute myeloid leukemia. Leukemia Research Reports, 2014, 3, 86-89.	0.4	14
165	Omacetaxine mepesuccinate in chronic myeloid leukemia. Expert Opinion on Pharmacotherapy, 2014, 15, 2397-2405.	1.8	13
166	Long-term response of refractory primary cold agglutinin disease to eculizumab therapy. Annals of Hematology, 2014, 93, 343-344.	1.8	20
167	Low 25(OH) vitamin D<sub>3</sub> levels are associated with adverse outcome in newly diagnosed, intensively treated adult acute myeloid leukemia. Cancer, 2014, 120, 521-529.	4.1	59
168	High pseudotumor cerebri incidence in tretinoin and arsenic treated acute promyelocytic leukemia and the role of topiramate after acetazolamide failure. Leukemia Research Reports, 2014, 3, 62-66.	0.4	7
169	Prolonged Administration of Azacitidine With or Without Entinostat for Myelodysplastic Syndrome and Acute Myeloid Leukemia With Myelodysplasia-Related Changes: Results of the US Leukemia Intergroup Trial E1905. Journal of Clinical Oncology, 2014, 32, 1242-1248.	1.6	227
170	Early versus Late Preemptive Allogeneic Hematopoietic Cell Transplantation for Relapsed or Refractory Acute Myeloid Leukemia. Biology of Blood and Marrow Transplantation, 2014, 20, 1369-1374.	2.0	5
171	Myelodysplastic syndromes and autoimmune diseases—Case series and review of literature. Leukemia Research, 2013, 37, 894-899.	0.8	66
172	Phase I/II Trial of Nanomolecular Liposomal Annamycin in Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, 430-434.	0.4	42
173	CD19 expression in acute leukemia is not restricted to the cytogenetically aberrant populations. Leukemia and Lymphoma, 2013, 54, 1517-1520.	1.3	19
174	Phase II trial of clofarabine and daunorubicin as induction therapy for acute myeloid leukemia patients greater than or equal to 60 years of age. Leukemia Research, 2013, 37, 1468-1471.	0.8	7
175	Down-regulation of signal transducer and activator of transcription 3 improves human acute myeloid leukemia-derived dendritic cell function. Leukemia Research, 2013, 37, 822-828.	0.8	15
176	Development of a Preclinical PK/PD Model to Assess Antitumor Response of a Sequential Aflibercept and Doxorubicin-Dosing Strategy in Acute Myeloid Leukemia. AAPS Journal, 2013, 15, 662-673.	4.4	14
177	Bortezomib Added to Daunorubicin and Cytarabine During Induction Therapy and to Intermediate-Dose Cytarabine for Consolidation in Patients With Previously Untreated Acute Myeloid Leukemia Age 60 to 75 Years: CALGB (Alliance) Study 10502. Journal of Clinical Oncology, 2013, 31, 923-929.	1.6	96
178	Activity of the Hypoxia-Activated Prodrug, TH-302, in Preclinical Human Acute Myeloid Leukemia Models. Clinical Cancer Research, 2013, 19, 6506-6519.	7.0	56
179	Acute Myeloid Leukemia, Version 2.2013. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 1047-1055.	4.9	135
180	Phase 1 trial of linifanib (ABT-869) in patients with refractory or relapsed acute myeloid leukemia. Leukemia and Lymphoma, 2012, 53, 1543-1551.	1.3	16

#	ARTICLE	IF	CITATIONS
181	Modulation of Chemotherapeutic Efficacy by Vascular Disrupting Agents: Optimizing the Sequence and Schedule. <i>Journal of Clinical Oncology</i> , 2012, 30, 760-761.	1.6	16
182	Acute Myeloid Leukemia. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 984-1021.	4.9	236
183	Cytoreduction with gemtuzumab ozogamicin and cytarabine prior to allogeneic stem cell transplant for relapsed/refractory acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2012, 53, 2085-2088.	1.3	6
184	Characterization of vancomycin pharmacokinetics in the adult acute myeloid leukemia population. <i>Journal of Oncology Pharmacy Practice</i> , 2012, 18, 91-96.	0.9	19
185	Acute Myeloid Leukemia Secondary to Oxaliplatin Treatment for Esophageal Cancer. <i>Clinical Colorectal Cancer</i> , 2012, 11, 151-154.	2.3	9
186	A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide. <i>Journal of Hematology and Oncology</i> , 2012, 5, 71.	17.0	56
187	Image cytometry-based detection of aneuploidy by fluorescence in situ hybridization in suspension. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2012, 81A, 776-784.	1.5	32
188	Clofarabine Plus Cytarabine Compared With Cytarabine Alone in Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia: Results From the CLASSIC I Trial. <i>Journal of Clinical Oncology</i> , 2012, 30, 2492-2499.	1.6	165
189	Smoking adversely affects survival in acute myeloid leukemia patients. <i>International Journal of Cancer</i> , 2012, 130, 1451-1458.	5.1	20
190	Is obesity a prognostic factor for acute myeloid leukemia outcome?. <i>Annals of Hematology</i> , 2012, 91, 359-365.	1.8	33
191	Vascular endothelial growth factor inhibition: Conflicting roles in tumor growth. <i>Cytokine</i> , 2011, 53, 115-129.	3.2	17
192	Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. <i>Blood</i> , 2011, 117, 3294-3301.	1.4	353
193	Acute Myeloid Leukemia. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011, 9, 280-317.	4.9	56
194	Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Cancer</i> , 2011, 117, 1583-1594.	4.1	103
195	Phase 1 study of arsenic trioxide, high-dose cytarabine, and idarubicin to downregulate constitutive signal transducer and activator of transcription 3 activity in patients aged <60 years with acute myeloid leukemia. <i>Cancer</i> , 2011, 117, 4831-4868.	4.1	16
196	Interpretation of cytogenetic and molecular results in patients treated for CML. <i>Blood Reviews</i> , 2011, 25, 139-146.	5.7	19
197	Myeloid blastic transformation of myeloproliferative neoplasms: A review of 112 cases. <i>Leukemia Research</i> , 2011, 35, 608-613.	0.8	32
198	Interferon- $\beta$ secretion by t(9;22) acute lymphoblastic leukemia-derived dendritic cells. <i>Leukemia Research</i> , 2011, 35, 275-277.	0.8	6

#	ARTICLE	IF	CITATIONS
199	Hypoxia-inducible factor-1 $\alpha$ protein expression is associated with poor survival in normal karyotype adult acute myeloid leukemia. <i>Leukemia Research</i> , 2011, 35, 579-584.	0.8	70
200	Hypoxia-Associated Effects on Reactive Oxygen Species Generation by Human Acute Myeloid Leukemia Cells. <i>Blood</i> , 2011, 118, 4998-4998.	1.4	4
201	Optimizing the Timing of Allogeneic Blood or Marrow Transplantation (BMT) in a Prospective Cohort of Relapsed or Refractory Acute Myeloid Leukemia (AML). <i>Blood</i> , 2011, 118, 3096-3096.	1.4	4
202	Anti-Vascular and Anti-Tumor Effects of the Vascular Disrupting Agent ASA404 (DMXAA) in Human Acute Leukemia Xenograft Models. <i>Blood</i> , 2011, 118, 4293-4293.	1.4	0
203	Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy. <i>Blood</i> , 2010, 116, 3163-3170.	1.4	143
204	Can decreasing smoking prevalence reduce leukemia mortality?. <i>Annals of Hematology</i> , 2010, 89, 873-876.	1.8	4
205	Recurrent deletion of 9q34 in adult normal karyotype precursor B-cell acute lymphoblastic leukemia. <i>Cancer Genetics and Cytogenetics</i> , 2010, 199, 15-20.	1.0	11
206	Genomic, immunophenotypic, and NPM1/FLT3 mutational studies on 17 patients with normal karyotype acute myeloid leukemia (AML) followed by aberrant karyotype AML at relapse. <i>Cancer Genetics and Cytogenetics</i> , 2010, 202, 101-107.	1.0	15
207	Pyridoxine treatment of vincristine-induced cranial polyneuropathy in an adult patient with acute lymphocytic leukemia: Case report and review of the literature. <i>Leukemia Research</i> , 2010, 34, e194-e196.	0.8	10
208	Aflibercept Exerts Antivascular Effects and Enhances Levels of Anthracycline Chemotherapy <i>In vivo</i> in Human Acute Myeloid Leukemia Models. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 2737-2751.	4.1	22
209	Subnormal Vitamin D Levels Are Associated with Adverse Outcome In Newly-Diagnosed Similarly-Treated Adult Acute Myeloid Leukemia (AML) Patients.. <i>Blood</i> , 2010, 116, 1041-1041.	1.4	4
210	Pegasparaginase: where do we stand?. <i>Expert Opinion on Biological Therapy</i> , 2009, 9, 111-119.	3.1	57
211	Acute myeloid leukemia and diabetes insipidus with monosomy 7. <i>Cancer Genetics and Cytogenetics</i> , 2009, 190, 97-100.	1.0	22
212	Treating octogenarian and nonagenarian acute myeloid leukemia patients—Predictive prognostic models. <i>Cancer</i> , 2009, 115, 2472-2481.	4.1	24
213	Targeting 11q23 positive acute leukemia cells with high molecular weight-melanoma associated antigen-specific monoclonal antibodies. <i>Cancer Immunology, Immunotherapy</i> , 2009, 58, 415-427.	4.2	12
214	Metachronous and synchronous presentation of acute myeloid leukemia and lung cancer. <i>Leukemia Research</i> , 2009, 33, 1208-1211.	0.8	8
215	Effect of Romiplostim in Patients (pts) with Low or Intermediate Risk Myelodysplastic Syndrome (MDS) Receiving Azacitidine. <i>Blood</i> , 2008, 112, 224-224.	1.4	13
216	Acute Myeloid Leukemia. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2008, 6, 962.	4.9	7

#	ARTICLE	IF	CITATIONS
217	Concomitant Presentation of Acute Myeloid Leukemia (AML) and Lung Cancer. <i>Blood</i> , 2008, 112, 3994-3994.	1.4	0
218	Targeting CD40. <i>Leukemia and Lymphoma</i> , 2007, 48, 229-231.	1.3	1
219	Remission of Philadelphia chromosome-positive central nervous system leukemia after dasatinib therapy. <i>Leukemia and Lymphoma</i> , 2007, 48, 1053-1056.	1.3	21
220	Frequent Molecular Aberrations in Normal Karyotype (NC) Precursor B-Cell Acute Lymphoblastic Leukemia (pB-ALL) Detected by Comparative Genomic Hybridization.. <i>Blood</i> , 2007, 110, 4270-4270.	1.4	0
221	The Effects of Anti-High Molecular Weight-Melanoma Associated Antigen (HMW-MAA) Monoclonal Antibodies (mAb) Against 11q23 Positive Acute Leukemia Cells.. <i>Blood</i> , 2006, 108, 4550-4550.	1.4	1
222	Effect of Bone Marrow Hypoplasia Secondary to Reinduction Therapy for Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) on Outcomes after Blood and Marrow Transplantation (BMT).. <i>Blood</i> , 2006, 108, 3033-3033.	1.4	0
223	Methotrexate and cytarabine inhibit progression of human lymphoma in NOD/SCID mice carrying a mutant dihydrofolate reductase and cytidine deaminase fusion gene. <i>Molecular Therapy</i> , 2004, 10, 574-584.	8.2	21
224	Telomerase inhibition with an oligonucleotide telomerase template antagonist: in vitro and in vivo studies in multiple myeloma and lymphoma. <i>Blood</i> , 2004, 103, 258-266.	1.4	85
225	Targeting autocrine and paracrine VEGF receptor pathways inhibits human lymphoma xenografts in vivo. <i>Blood</i> , 2004, 104, 2893-2902.	1.4	124
226	Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma. <i>Cancer</i> , 2003, 98, 1196-1205.	4.1	154
227	Activity of a Novel Anti-folate (PDX, 10-propargyl 10-deazaaminopterin) against Human Lymphoma is Superior to Methotrexate and Correlates with Tumor RFC-1 Gene Expression. <i>Leukemia and Lymphoma</i> , 2003, 44, 1027-1035.	1.3	107
228	Acute myeloid leukemia with t(5;18)(q35;q21). <i>Cancer Genetics and Cytogenetics</i> , 2001, 127, 71-73.	1.0	5